Sterlacci et al. demonstrated that the phenotype CD24−/CD44+ did not show a significant difference in overall survival for the entire NSCLC cohort when compared with the CD24+/CD44 −population. This evidence concerns the gene CD44 and non-small cell lung carcinoma.